PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.25%
Negative revenue growth while CRON.TO stands at 114.03%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-11.81%
Negative gross profit growth while CRON.TO is at 87.42%. Joel Greenblatt would examine cost competitiveness or demand decline.
-1070.05%
Negative EBIT growth while CRON.TO is at 172.66%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-1070.05%
Negative operating income growth while CRON.TO is at 98.74%. Joel Greenblatt would press for urgent turnaround measures.
433.16%
Net income growth at 75-90% of CRON.TO's 560.97%. Bill Ackman would press for improvements to catch or surpass competitor performance.
306.74%
EPS growth under 50% of CRON.TO's 710.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
306.74%
Diluted EPS growth under 50% of CRON.TO's 912.50%. Michael Burry would worry about an eroding competitive position or excessive dilution.
17.10%
Share count expansion well above CRON.TO's 1.71%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
16.43%
Slight or no buyback while CRON.TO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
437.30%
OCF growth above 1.5x CRON.TO's 170.59%. David Dodd would confirm a clear edge in underlying cash generation.
-403.23%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
197.22%
OCF/share CAGR of 197.22% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
197.22%
OCF/share CAGR of 197.22% while CRON.TO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
750.80%
3Y OCF/share CAGR above 1.5x CRON.TO's 313.09%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
253.30%
10Y net income/share CAGR of 253.30% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
253.30%
Net income/share CAGR of 253.30% while CRON.TO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
386.95%
3Y net income/share CAGR above 1.5x CRON.TO's 163.99%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
964.68%
Equity/share CAGR of 964.68% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
964.68%
Equity/share CAGR of 964.68% while CRON.TO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
2364.73%
3Y equity/share CAGR above 1.5x CRON.TO's 385.61%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.82%
Firm’s AR is declining while CRON.TO shows 34.15%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-5.96%
Inventory is declining while CRON.TO stands at 45.11%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
48.98%
Similar asset growth to CRON.TO's 51.11%. Walter Schloss finds parallel expansions or investment rates.
28.76%
75-90% of CRON.TO's 36.50%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
18.59%
Debt growth of 18.59% while CRON.TO is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
10.45%
R&D growth of 10.45% while CRON.TO is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
34.18%
We expand SG&A while CRON.TO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.